Evaluation of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) effects on left ventricular (LV) pump function, LV filling pressure (LVFP), and right ventricular systolic pressure (RVSP) during exercise in T2DM patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.